IRON CLAD: Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose Injection) in Adults

Trial Profile

IRON CLAD: Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose Injection) in Adults

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Chemotherapy-induced anaemia; Iron deficiency anaemia
  • Focus Therapeutic Use
  • Acronyms IRON CLAD
  • Sponsors Luitpold Pharmaceuticals
  • Most Recent Events

    • 18 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 18 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jan 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top